Thus, the coexpression pattern between ERBB2 and other genes, such as PGAP3, STARD3, and PNMT, may be a marker of cancer, and site mutations in the interaction anchors or dysregulation in interactions related to ERBB2 may be a new target for cancer studies. The gene discussed is PNMT; the disease is cancer.